比较GLP-1激动剂对生活方式干预和体重控制能力的影响 关于耻辱和体重相关认知信息的比较
Stacy M Post1, Michelle L Stock2, Susan Persky3
1The George Washington University, Washington, DC, USA. spost5@gwu.edu.
International journal of behavioral medicine
|February 11, 2025
概括
使用类似葡萄糖1受体激动剂 (GLP-1s) 减肥导致比饮食和运动更具负面判断力,部分原因是由于社会比较. 体重可控性框架对体重耻辱和相关认知的影响有限.
科学领域:
- 行为科学 行为科学
- 肥胖问题研究研究
- 社会心理学 社会心理学
背景情况:
- 社会判断往往将葡萄糖类1受体激动剂 (GLP-1s) 标记为减肥的"捷径".
- 对体重控制能力的信念与反脂肪态度和不适应体重行为的相关性.
- 社会比较过程可能会调解减肥方法对耻辱的影响.
研究的目的:
- 调查体重控制能力和减肥方法 (GLP-1与饮食/运动) 如何影响体重耻辱和不适应性认知.
- 检查社会比较在这些影响中的作用.
主要方法:
- 163名超重/肥胖女性接受了不同的情景,包括体重可控性和减肥方法.
- 参与者报告了社会比较 (总体下降,体重/体型) 和体重耻辱的态度.
- 评估了与体重相关的不适应性认知 (暴饮暴食,限制性饮食,过度运动).
主要成果:
- 与饮食/运动相比,GLP-1的使用导致了更多的负面判断,通过全球向下社会比较进行调解.
- 饮食/运动描述通过体重/体型比较增加了不适应性认知.
- 将体重定为不太可控并没有减少对GLP-1使用者的耻辱.
结论:
- 减肥方法显著影响社会判断和不适应性认知.
- 体重可控性框架在减少体重耻辱的有效性有限.
- 需要进一步的研究来开发针对体重耻辱和不适应性认知的干预措施.
相关概念视频
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Oral Hypoglycemic Agents: Biguanides and Glitazones
160
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
160
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Stress Prevention and Stress Management Techniques VI
26
Adopting a healthier lifestyle often requires overcoming significant challenges, but leveraging psychological, social, and cultural resources can facilitate meaningful change. Effective self-change hinges on understanding and applying key tools such as motivation and goal setting, which help sustain efforts toward long-term health benefits.
Motivation and Self-Determination
Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
Motivation and Self-Determination
Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
26
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149


